°ª¦åÀ£Á{§ÉªvÀø«ü¤Þ (¤G)
ªí¡]¤»¡^¨Ï¥Î°À£¾¯ªvÀø¡A¹ï¦P®É¦ñ¦³¨ä¥L¯e¯f¤§¦n¡BÃa¼vÅT
ARCH INTERN MED/VOL 157, NOV 24, 1997
¦X¨Ö¯e¯f ÃĪ«ªvÀø
³Ì¨Î¿ï¾ÜÃĪ«
²Ä¤@«¬¿}§¿¯f¨Ö³J¥Õ§¿: ACE inhibitors
¤ßŦ°IºÜ: ACE inhibitors Diuretics
¦Ñ¦~¿W¥ß¦¬ÁY©Ê°ª¦åÀ£: ACE inhibitors Ca++ Channel blockers¡]ªø®Ä«¬DHP¡^
Diuretics
¤ß¦Ù±ð¶ë ACE inhibitorsµù¡G¦X¨Ö¤ß°IºÜ £] Blockers
¡]«ünon-ISA¡^
¦³§U¯q¤§¿ï¾ÜÃĪ«
¤ßµ±µh £] Blockers Ca++ Channel blockers
¤ß©ÐÀW¯ß¡BÅÖºû²Ó°Ê £] Blockers Ca++ Channel blockers
¡]«ünon-DHP¡^
²Ä1¡B2«¬¿}§¿¯f¨Ö³J¥Õ§¿ ACE inhibitors¡]¸û¦n¡^ Ca++ Channel blockers
²Ä2«¬¿}§¿¯f ACEI ¡³µù
Diuretics
¡]§C¾¯¶q¡^
¥»ºA©ÊŸ§Ý £] Blockers¡]«ünon-cardioselective¡^
¤ß°IºÜ ACE inhibitors Ca++ Channel blockers
¡]«üamlodipine, felodipine¡^ Carvedilol
¥Òª¬¸¢¤®¶i¯g £] Blockers
°¾ÀYµh £] Blockers Ca++ Channel blockers
¡]«ünon-DHP¡^
¤ß¦Ù±ð¶ë¡]µL¤ß°IºÜ¡^ Ca++ Channel blockers¡]«üDiltiagem, Verapamil¡^
°©½è²¨ÃP¯g Diuretics
¡]«üthiazides¡^
¤â³N«e°ª¦åÀ£ £] Blockers
ÄáÅ@¸¢ªÎ¤j¦å¯×²§±` £\ Blockers
µÇ°IºÜ¡]¤p¤ßµÇ¦åºÞ©Ê°ª¦åÀ£¨Ö¦Ù»ÄÓþ¡Ù3mg/dl¡^ ACE inhibitors
¥i¯à¤Ï¦Ó¦³®`¤§ÃĪ«¡]¡±¡Gªí¸T§Ò!¡^
¤ä®ðºÞ®ð³Ý £] Blockers¡±
©PÃä¦åºÞ¯e¯f £] Blockers
¼~Æ{¯g £] Blockers Central £\ agonists Reserpine¡±
²Ä1¡B2«¬¿}§¿¯f(µL¦X¨Ö¤ßŦ¯f¡BÄY«°ª¦åÀ£) £] Blockers ¡³µù
Diuretics
¡]µù«ü¤j¾¯¶q¡^
¦å¯×²§±` £] Blockers
¡]«ü«DISA¡^ Diuretics
¡]µù«ü¤j¾¯¶q¡^
µh· Diuretics
²Ä¤G¡B¤T«×©Ð«Çªýº¢ £] Blockers¡± Ca++ Channel blockers
¡]«ünon DHP¡±¡^
¤ßŦ°IºÜ £] Blockers
¡]°£Carvedilol¡^ Ca++ Channel blockers
¡]°£amlodipine¤Îfelodipine¡^
Ãh¥¥ ACE inhibitors¡± Angiotension II antagonists¡±
µÇ¦åºÞ°ª¦åÀ£ ACE inhibitors Angiotension II antagonists
¨x¯f £\-methyldopa¡± Labetalol
µÇ°IºÜ Potassium sparing agents
»¡©ú¡GISA=Intrinsic Sympathomimetic activity , DHP=Dihydropyridines
¡³µù¡G¨ÌUK Prospective Diabetes study, ¦@1148¦W²Ä¤G«¬¿}§¿¯f¤§°ª¦åÀ£±wªÌ¡Aªø¹F¤K¦~°lÂܵo²{¡A¨Ï¥ÎACE§í¨î¾¯©Î£]ªýÂ_¾¯¦bªvÀø¤j¦åºÞ©Î·L¦åºÞ¯fÅܳ£¯àÀò±o¦n³B¡A¥Bµo²{¦åÀ£±±¨î¸ûÄYÂÔ²Õ¡]144/82mmHg¡^¤ñ¦åÀ£ºû«ù¦b154/87mmHg²Õ¡A¯à°§C1/3¦º¤`²v¡A1/2¸£¤¤·¤Î1/2·L¦åºÞ¯fÅÜ¡C
¹Ï¡]¤G¡^°ª¦åÀ£ÃĪ«¤§§@¥Î³¡¦ì¤Î¾÷Âà
»¡©ú¡Gºû«ù¦åÀ£¤§¥Í²z¾÷Âà«D±`½ÆÂø¡F¼s¸q¨¥¡A¦åÀ£¬°¤ß³Õ¥X¶q»P©PÃä¦åºÞªý¤O¤§²Õ¦X¡C°ª¦åÀ£ªvÀø¨Ã«D§¹¥þ¨Ì¿àÃĪ«¡A©|¶·°t¦X«DÃĪ«ªvÀø¡A§ïÅܥͬ¡§ÎºA¡CÃĪ«ªvÀø¡A½Ð¿í¦uÃĪ«¨Ï¥Îì«h¡C¹Ï" "ªí¿³¾Ä§@¥Î¡F" "ªí¥ÜªýÂ_
ACE§í¨î¾¯¡A¦b°ªµÇ¯À°ª¦åÀ£¬°³Ì¨ÎÃĪ«¡F§CÆQ¡B§C¾¯¶q§Q§¿¾¯¦X¨ÖACE§í¨î¾¯¡A¬°«Ü¦X¾A¤§¨Ö¥ÎÃĪ«¡A¦ýACE§í¨î¾¯¹ï¥¿±`©Î§CµÇ¯À°ª¦åÀ£¤]¦³®Ä¡C ªí¡]¤K¡^°À£Àø®Ä¤£¨Î¤§ì¦]
ú@ °²©Ê°ª¦åÀ£¤§ì¦] |
³æ¿W©Ê¶E©Ò°ª¦åÀ£
¹ïªÎD¯f¤H¨Ï¥Î¸û¤p¤§À£¯ß±a¡C |
úA ¹x©T©Ê°ª¦åÀ£¤§ì¦] |
¥¼³Q¹îı¤§Äòµo©Ê°ª¦åÀ£ [µù¡GµÇ¦åºÞ¤Î¤º¤Àªc©Ê°ª¦åÀ£(µÇ¤W¸¢¥Ö½è½F¡Bìµo©Ê adolsteronism¡Bpheochromocytoma ¡B¥Òª¬¸¢©Î°Æ¥Òª¬¸¢¯e¯f)¡B©Î¥D°Ê¯ß¯U¯¶]
¹ïªvÀø¤§¶¶±q©Ê¤£¨Î
«ùÄò¨Ï¥Î³y¦¨¦åÀ£¤W¤É¤§ÃĪ«¡]¦p®øª¢¸Ñ¼öÂíµh¾¯¡B¤fªAÁ×¥¥ÃÄ¡B¥Ì¯ó¡B¥i«Ý¦]¡] codeine¡^¡BÃþ©T¾JªvÀø¡B¦w«D¥L©R¡C¨Ï¥Î¬õ¦å²y¥Í¦¨¯À¡]erythropoietin¡^¡BÀôÌUÆF¡]cyclosporins¡^¡B »óÂH½¤¦¬ÁY¾¯¡]§Y»ó¸Ñ¥R¦å¾¯¡ANasal decongestants¡^
Åé²G¹L¶q¡A°ª ¶u¶¼ ¹¡A¶i¦æ©ÊµÇ¥\¯à¤£¥þ¡A§Q§¿¾¯¥Î¶q¤£¨¬
µLªk§ïµ½¥Í¬¡«¬ºA¡A¤j¶q¶¼°s¡B§l µÒ ¡AÅ髤W¤É |
µù¡G¥Í¬¡§ÎºA¥¼§ïÅÜ¡BÃĪ«¾¯¶q¤£¨¬»P¤£¾A·í¤§ÃĪ«¨Ö¥Î¡A ±`¾ÉP°À£Àø®Ä¤£¨Î¡C
¹Ï¡]¤T¡^ ¶}©l°¦åÀ£ªvÀø«á¤§°lÂܬyµ{
|
¶}©l°¦åÀ£ÃĪ«ªvÀø |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
<
¦åÀ£¤w¹FªvÀø¥Ø¼ÐÈ |
|
|
¦b¥¿±`¾¯¶q¤U¤´¥¼¹F¥Ø¼ÐÈ |
|
µo¥Í°Æ§@¥Î |
|
|
°ª¤Î¶W°ª«×¦MÀI |
¤¤¤Î§C«×¦MÀI |
|
|
¦p¨S¦³¤ÏÀ³¡A¥Ñ¨ä¥L¤ÀÃþ¤¤´«ÃĩαħC¾¯¶q¨Ö¥Î¨ä¥LÃĪ«
¦p¥u¦³³¡¥÷¤ÏÀ³¡A¥[¤J¨ä¥LÃþ§O¤§ÃĪ«¡F©Î§ï¥Î§C¾¯¶q¨Ö¥ÎÃĪ«
¥[±j§ïµ½¥Í¬¡«¬ºA |
|
¥Ñ¨ä¥L¤ÀÃþ¤¤´«ÃÄ©Î
°§C¾¯¶q¤Î¥[¤J¨ä¥LÃþ§O¤§ÃĪ« |
¨C¤TÓ¤ë°lÂܦåÀ£¤Î¦MÀI¦]¤l
¥[±j§ïµ½¥Í¬¡«¬ºA |
¨C¤»Ó¤ë°lÂܦåÀ£¤Î¦MÀI¦]¤l
¥[±j§ïµ½¥Í¬¡«¬ºA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
¸Õ¹Ï´î¤Ö¨Ö¥ÎÃĪ«ªººØÃþ©Î¾¯¶q |
|
|
Ãø¥H±±¨î¤§°ª¦åÀ£¡A¦A¥[²Ä¤TÃþÃĪ«
¡]YµL¸T§Ò¡A¥²¥]¬A§Q§¿¾¯¦b¤º¡^ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
¦A½Õ¾ãÃĪ«¾¯¶q©Î¦A¼W¥[·sÃĪ½¦Ü±±¨î¨ì¥Ø¼Ð¦åÀ£¡A©ÎÂश°ª¦åÀ£±M®a |
µù¡G 1.YµL§Q§¿¾¯¤§¨Ï¥Î¸T§Ò¡AÀ³ÁקK¦P®É¦X¨Ö¨Ï¥Î¤TºØ°ª»ù°À£¾¯¡C
2.µL¦X¨Ö¯g¤§²Ä¤G¯Å°ª¦åÀ£¥H¤W¡A¤j³¡¤À¶·¨Ï¥Î¨âºØÃĪ«²Õ¦X¡A±`¬°thiazideÃþ§Q§¿¾¯¦X¨ÖACE§í¨î¾¯¡B¦åºÞ±i¤O¯À«ú§Ü¾¯¡B£]ªýÂ_¾¯©Î¶tÂ÷¤lªýÂ_¾¯¡C
|